9da00140.h_-_UcxD0VsYZ-oqWItm7GpEdvb69q8c9kreat8lp8w.7Lb2OY4wuiNaV5hlHLMl3SMCG7OWl5Z9lx-sOI1kyY2wnc0ykzXhKU8dsw
11-13 Zai Lab Announces First-Time Inclusion of KarXT and VYVGART Hytrulo® in China’s 2026 National Reimbursement Drug List, Expanding Access to Key Growth Products BU
11-13 Zai Lab Announces Participation in Investor Conferences in November 2026 BU
11-13 Zai Lab Limited - Special Call
11-13 Zai Lab Says Experimental Drug Reduced Activity of Protein Linked to Atopic Dermatitis by at Least 90% MT
11-13 Zai Lab Presents Positive First-in-Human Data for ZL-1503, a Novel IL-13/IL-31Rα Bispecific, Demonstrating Rapid and Sustained Inhibition of Key Atopic Dermatitis Biomarkers and Extended Serum Half-Life Supporting Less Frequent Dosing BU
11-08 Zai Lab Limited announced that it has received $249.9336 million in funding from a group of investors CI
11-06 Zai Lab Q3 Performance Meets Expectations With Pivotal 2027 Ahead, UBS Says MT
11-05 Zai Lab Q3 Loss Widens, Revenue Declines MT
11-05 Zai Lab Limited, Q3 2026 Earnings Call, Nov 05, 2026
11-05 Zai Lab Presents Updated Clinical Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Clinically Meaningful Responses and a Manageable Safety Profile in Previously Treated Extrapulmonary Neuroendocrine Carcinomas BU
11-05 Zai Lab Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026 CI
11-05 Earnings Flash (ZLAB) Zai Lab Limited Reports Q3 Revenue $108.2M, vs. FactSet Est of $107.9M MT
11-05 Earnings Flash (ZLAB) Zai Lab Limited Reports Q3 Revenue $108.2M, vs. FactSet Est of $107.9M MT
11-05 Earnings Flash (ZLAB) Zai Lab Limited Reports Q3 Loss of $0.41 per ADS, vs. FactSet Est of $-0.58 MT
11-05 Zai Lab Announces Third Quarter 2026 Financial Results and Recent Corporate Updates BU
10-26 Zai Lab Limited announced that it has received $249.9336 million in funding CI
10-26 Zai Lab's Lung Cancer Drug Achieves Promising Response Rate in Phase 1b Trial; Shares up 4% MT
10-23 Zai Lab Limited - Special Call
10-23 Zai Lab Says Zoci Plus Atezolizumab Improves Response Rate in Phase 1 Lung Cancer Trial MT
10-23 Zai Lab Limited Shares First Data From Global Phase 1b Clinical Trial Evaluating Zocilurtatug Pelitecan In Combination With Atezolizumab With And Without Carboplatin As First-Line Treatment For Extensive-Stage Small Cell Lung Cancer CI
10-23 Zai Lab’s Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer BU
10-23 Zai Lab to Privately Place $250 Million in ADRs to Fund Drug Research MT
10-22 Zai Lab to Raise $250 Million in Private Placement of ADSs MT
10-22 Zai Lab Announces $250 Million Private Placement BU
10-21 Zai Lab Limited announced that it expects to receive $249.9336 million in funding CI

Become a member to access more news

New member
No results match your criteria
  1. Stock Market
  2. Stocks
  3. ZLAB Stock
  4. News Zai Lab Limited